SG122738A1 - Compositions and methods for the prevention and diagnosis of lyme disease - Google Patents

Compositions and methods for the prevention and diagnosis of lyme disease

Info

Publication number
SG122738A1
SG122738A1 SG200004033A SG200004033A SG122738A1 SG 122738 A1 SG122738 A1 SG 122738A1 SG 200004033 A SG200004033 A SG 200004033A SG 200004033 A SG200004033 A SG 200004033A SG 122738 A1 SG122738 A1 SG 122738A1
Authority
SG
Singapore
Prior art keywords
diagnosis
prevention
compositions
methods
lyme disease
Prior art date
Application number
SG200004033A
Other languages
English (en)
Inventor
Richard A Flavell
Fred S Kantor
Stephen W Barthold
Erol Fikrig
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of SG122738A1 publication Critical patent/SG122738A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG200004033A 1990-06-15 1991-06-13 Compositions and methods for the prevention and diagnosis of lyme disease SG122738A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53896990A 1990-06-15 1990-06-15
US60255190A 1990-10-26 1990-10-26
US68235591A 1991-04-08 1991-04-08

Publications (1)

Publication Number Publication Date
SG122738A1 true SG122738A1 (en) 2006-06-29

Family

ID=27415285

Family Applications (2)

Application Number Title Priority Date Filing Date
SG1996001704A SG47447A1 (en) 1990-06-15 1991-06-13 Compositions and methods for the prevention and diagnosis of lyme disease
SG200004033A SG122738A1 (en) 1990-06-15 1991-06-13 Compositions and methods for the prevention and diagnosis of lyme disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG1996001704A SG47447A1 (en) 1990-06-15 1991-06-13 Compositions and methods for the prevention and diagnosis of lyme disease

Country Status (6)

Country Link
US (3) US5747294A (fr)
EP (1) EP0536335A4 (fr)
JP (1) JPH06501382A (fr)
CA (1) CA2084413A1 (fr)
SG (2) SG47447A1 (fr)
WO (1) WO1992000055A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
DE4015911A1 (de) 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
EP0465204B1 (fr) * 1990-07-06 2000-09-20 American Home Products Corporation Vaccin contre la maladie de lyme
CA2057536C (fr) * 1990-12-21 1999-10-26 John J. Dunn Clonage et expression des lipoproteines de borrelia
US6676942B1 (en) * 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
EP0878545A3 (fr) * 1991-08-15 1998-12-16 SMITHKLINE BEECHAM BIOLOGICALS s.a. Protéines OspA des sous-groupes borrelia burgdorferi, gènes codants et vaccins
AU2903892A (en) * 1991-10-22 1993-05-21 Symbicom Aktiebolag Improvement in (borrelia burgdorferi) diagnosis and prophylaxis
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
EP0671926B1 (fr) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Peptides immunomodulateurs
CA2105629A1 (fr) * 1992-09-14 1994-03-15 Robert S. Becker Potentialisation de la reaction immunogenique
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
DK0757556T3 (da) * 1994-04-11 2006-10-02 Wyeth Corp Borrelia Burgdorferi-bakterin
US6248517B1 (en) 1995-04-24 2001-06-19 The Texas A & M University System Decorin binding protein compositions and methods of use
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
US6312907B1 (en) 1995-04-24 2001-11-06 The Texas A & M University System DbpA compositions and methods of use
US6214355B1 (en) 1995-04-24 2001-04-10 Texas A & M University System DbpA compositions
US5932220A (en) 1995-05-08 1999-08-03 Board Of Regents University Of Texas System Diagnostic tests for a new spirochete, Borrelia lonestari sp. nov.
ES2271954T3 (es) * 1995-06-07 2007-04-16 Sanofi Pasteur Inc. Expresion de lipoproteinas.
ZA964896B (en) 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
ES2270523T3 (es) 1997-06-30 2007-04-01 The Administrators Of The Tulane Educational Fund Antigenos de superficie y proteinas utiles en composiciones para la diagnosis y prevencion de la enfermedad de lyme.
ATE386805T1 (de) 1998-07-31 2008-03-15 Gundersen Lutheran Medical Fou Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff
US6610306B2 (en) * 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
EP1865062A3 (fr) * 2000-08-18 2008-01-09 Research Foundation Of State University Of New York OspA modifiée de Borrelia burgdorferi
WO2002016421A2 (fr) * 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Ospa du borrelia burgdorferi modifie
US8821893B2 (en) * 2004-07-02 2014-09-02 Bio Peptides, Corp. Oral vaccine for Borrelia
KR101192127B1 (ko) 2006-11-03 2012-10-17 쉐링-프라우 리미티드 개 라임병 백신
US7546018B2 (en) 2007-01-13 2009-06-09 Ofs Fitel, Llc Fiber optic cabling for multi-dwelling unit (MDU) and commercial building deployments
WO2008116468A2 (fr) 2007-03-26 2008-10-02 Dako Denmark A/S Complexes peptidiques du cmh et leurs utilisations dans des maladies infectieuses
EP3023436A1 (fr) 2007-07-03 2016-05-25 Dako Denmark A/S Procédés améliorés pour produire, marquer et utiliser des multimères du cmh
EP2197908A2 (fr) 2007-09-27 2010-06-23 Dako Denmark A/S Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US20110262475A1 (en) * 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
WO2010009735A2 (fr) 2008-07-23 2010-01-28 Dako Denmark A/S Analyse et réparation combinatoires
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
EP2501719B1 (fr) * 2009-11-17 2015-11-04 Abaxis, Inc. Peptides et procédés pour la détection d'anticorps contre la maladie de lyme
EP3705133A3 (fr) * 2010-05-14 2021-01-06 Baxalta Incorporated Chimères d'ospa et leur utilisation dans des vaccins
US20120142023A1 (en) * 2010-12-02 2012-06-07 Ascoli Carl A Proteins and method for detection of lyme disease
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
US9816991B2 (en) 2012-02-01 2017-11-14 Biopeptides Corporation Diagnostic peptides for lyme disease
US9562079B2 (en) 2012-04-18 2017-02-07 Zoetis Services Llc Vaccines and methods to treat lyme disease in dogs
WO2015085323A1 (fr) 2013-12-06 2015-06-11 Biopeptides Corp. Peptides destinés au diagnostic de la maladie de lyme

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004411A1 (fr) * 1988-10-24 1990-05-03 Symbicom Aktiebolag Fractions de borrelia burgdorferi avec action immunogene
CA2025597A1 (fr) * 1989-09-19 1991-03-20 Markus M. Simon Vaccin contre la maladie de lyme
CA2072008A1 (fr) * 1989-12-22 1991-06-23 Renate Fuchs Proteines a activite immunologique provenant de borrelia burgdorferi, trousses de dosage contenant ces proteines et permettant la detection d'anticorps dans des milieux liquides, et utilisation de ces proteines comme vaccins contre les infections causees par differentes souches de borrelia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4754065A (en) * 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4691009A (en) * 1984-12-26 1987-09-01 Repligen Corporation Hybrid proteins produced by an ultrahigh prokaryotic expression system
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4721617A (en) * 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US4963483A (en) * 1987-10-13 1990-10-16 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
US5227293A (en) * 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
CA2025178A1 (fr) * 1989-10-02 1991-04-03 William G. Weisburg Sondes d'acide nucleique pour la detection des spirochetes de la maladie de lyme
US5217872A (en) * 1990-02-27 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Method for detection of borrelia burgdorferi antigens
CA2057536C (fr) * 1990-12-21 1999-10-26 John J. Dunn Clonage et expression des lipoproteines de borrelia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004411A1 (fr) * 1988-10-24 1990-05-03 Symbicom Aktiebolag Fractions de borrelia burgdorferi avec action immunogene
CA2025597A1 (fr) * 1989-09-19 1991-03-20 Markus M. Simon Vaccin contre la maladie de lyme
CA2072008A1 (fr) * 1989-12-22 1991-06-23 Renate Fuchs Proteines a activite immunologique provenant de borrelia burgdorferi, trousses de dosage contenant ces proteines et permettant la detection d'anticorps dans des milieux liquides, et utilisation de ces proteines comme vaccins contre les infections causees par differentes souches de borrelia

Also Published As

Publication number Publication date
JPH06501382A (ja) 1994-02-17
EP0536335A4 (en) 1993-07-14
US6197301B1 (en) 2001-03-06
WO1992000055A1 (fr) 1992-01-09
EP0536335A1 (fr) 1993-04-14
US6344552B1 (en) 2002-02-05
SG47447A1 (en) 1998-04-17
US5747294A (en) 1998-05-05
CA2084413A1 (fr) 1991-12-16

Similar Documents

Publication Publication Date Title
SG122738A1 (en) Compositions and methods for the prevention and diagnosis of lyme disease
AU6905391A (en) Methods and compositions for the treatment of hodgkin's disease
EP0808324A4 (fr) Compositions destinees au traitement et au diagnostic de maladies cardio-vasculaires et techniques correspondantes
AU5355094A (en) Therapeutic and diagnostic imaging compositions and methods
EP0546728A3 (en) Physiological tear compositions and methods for their preparation
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
GB9008788D0 (en) Diagnostic equipment
EP0542914A4 (en) Improved diagnostic and therapeutic compositions
IL105216A0 (en) Method and kit for the diagnosis of alzheimer's disease
GB8900678D0 (en) Compositions for the prevention and medical treatment of parodonthopathy
EP0557388A4 (en) Diagnosis and treatment of multiple sclerosis
GB9006671D0 (en) Diagnostic method and compositions
ZA914435B (en) Treatment of disease
HU9202431D0 (en) Medical preparatives of local application
AU4841296A (en) Diagnosis of and compositions and methods for the treatment of disease
EP0643586A4 (fr) Compositions utilisees dans le diagnostic et la prophylaxie de la maladie de lyme.
HUP0000570A3 (en) Use of 17 alpha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
IL93139A0 (en) Pharmaceutical compositions comprising suramin and methods for the use thereof
IL107515A0 (en) Diagnosis of mental disorders
GB9010190D0 (en) Composition for the treatment of protozoal disease and their use
HUP0000476A3 (en) Use of 17 betha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
HU9303488D0 (en) Controlled precipitation of particulate diagnostic imaging contrast agents
IL88936A0 (en) Compositions for the prevention and treatment of periodontal disease
GB9122858D0 (en) Method of disease diagnosis
GB9123755D0 (en) Method of disease diagnosis